Vol. 2 No. 3 (2025)

ONLINE ISSN :3007-309X
PRINT ISSN :3007-3081

Journal of Medical & Health Sciences Review

AI FOR PREVENTIVE HEALTHCARE, A DEEP LEARNING FRAMEWORK FOR EARLY DIAGNOSIS OF NEURODEGENERATIVE DISORDERS

Muhammad Ahmad Shahid[1], Muhammad Abdullah Awan[2], Shehryar Ali[2], Abdur Rafay Goraya[2], Aayan Umer[2]

[1] Department of Computer Science, Pakistan Embassy College Beijing, China
[2]Senior School, Aitchison College Lahore, Pakistan

ARTICLE INFO:

Keywords:
Artificial Intelligence (AI), Preventive Healthcare, Neurodegenerative Disorders, Deep Learning, Ethical Considerations

Corresponding Author:
Muhammad Ahmad Shahid,
Department of Computer Science, Pakistan Embassy College Beijing, China
Email:
ahmad.shahid.129@gmail.com

Article History:
Published on 18 August 2025

ABSTRACT

The integration of Artificial Intelligence (AI), particularly deep learning techniques, into preventive healthcare has opened new avenues for the early detection and management of neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. These conditions, marked by progressive neuronal decline, affect millions globally and pose significant diagnostic challenges, especially in their early stages. AI-driven models, utilizing diverse datasets like medical imaging and electronic health records, have demonstrated the capacity to identify subtle patterns indicative of disease onset with greater speed and accuracy than traditional methods. This capability facilitates personalized and timely interventions, potentially altering the course of disease progression and improving patient outcomes. However, the adoption of AI in clinical practice also raises critical concerns, including data privacy, algorithmic bias, and the transparency of machine-generated decisions. Ethical considerations surrounding fairness and accountability continue to shape the discourse on responsible AI deployment in healthcare. As the field advances, emphasis on rigorous validation, cross-population reliability, and robust regulatory oversight remains essential to ensure safe and equitable implementation. This paper explores the transformative potential of AI in preventive neurology while addressing the technological, ethical, and practical challenges that must be navigated for its successful integration into real-world clinical settings.

Summary

Artificial Intelligence (AI) for preventive healthcare, specifically through deep learning frameworks, represents a groundbreaking approach to the early diagnosis of neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. These conditions, characterized by the gradual loss of neuronal function, affect millions worldwide, with Alzheimer's alone impacting an estimated 50 million people, a number expected to triple by 2050. [1][2] As traditional diagnostic methods can be slow and prone to misdiagnosis, particularly in the early stages of these diseases, the integration of AI technologies offers promising avenues for improving diagnostic accuracy and accelerating treatment intervention. [3][4][5]

AI technologies, particularly machine learning (ML) and deep learning (DL), leverage vast datasets to identify patterns that may indicate the onset of neurodegenerative disorders much earlier than conventional approaches. These techniques utilize di-verse data types, including medical images and electronic health records, enabling healthcare providers to implement preventive strategies and personalized treatment plans tailored to individual patient profiles.[6][7][8] The significance of this integration lies in its potential to not only enhance diagnostic precision but also fundamentally transform the preventive healthcare landscape, allowing for timely interventions that can alter disease trajectories and improve patient outcomes.[9][10]

Despite the promise that AI holds, the deployment of these technologies is not without challenges. Concerns surrounding data privacy, algorithmic bias, and the interpretability of AI decision-making processes have emerged as prominent issues that require thorough examination and proactive management.[11][12][13] Ethical considerations regarding the fairness of AI systems and their accountability in clinical applications continue to prompt discussions among researchers and practitioners alike, highlighting the need for a balanced approach that prioritizes both innovation and responsible healthcare practices.[10][12]

As research in this field continues to evolve, the focus on translating AI advancements into real-world clinical settings remains paramount. Rigorous testing and validation of AI algorithms are essential to ensure their reliability and effectiveness across diverse patient populations, thereby enhancing trust and acceptance among healthcare providers and patients alike. The ongoing dialogue around ethical frameworks and regulatory standards will play a critical role in shaping the future of AI in preventive healthcare, particularly in addressing the complexities associated with neurodegenerative disorder management. [14][13]

Background

Neurodegenerative disorders encompass a variety of conditions characterized by the progressive loss of neurons, which often leads to significant cognitive and functional decline. Among these, Alzheimer's disease (AD) is the most prevalent form of dementia, affecting approximately 50 million people globally, a figure projected to triple by 2050[1][2]. The disease is typically categorized into three stages: early-stage (mild), middle-stage (moderate), and late-stage (severe) [15]. In the early stage, individuals may experience mild memory loss and confusion, while moderate stage patients face more profound memory loss and can exhibit mood changes, hallucinations, and anxiety [15]. By the severe stage, patients often become completely dependent on others for care, showing symptoms such as weight loss and loss of communication abilities [15].

The diagnosis of neurodegenerative diseases relies on various methods, including laboratory tests, imaging scans, and, in some cases, histopathological analysis post-mortem [3]. However, traditional diagnostic techniques can be time-consuming and may lead to misdiagnosis, particularly in diseases like Parkinson's disease (PD), where early symptoms can be subtle and attributed to other conditions [4][5] [36] [37] [40].

In recent years, advancements in artificial intelligence (AI) have opened new avenues for the early detection and diagnosis of neurodegenerative disorders. AI algorithms have shown promise in interpreting medical images and analyzing health records, leading to faster and more accurate diagnoses than conventional methods [4][6]. Machine learning (ML) and deep learning (DL) techniques are being increasingly employed to enhance diagnostic accuracy and facilitate the identification of neurodegenerative diseases at earlier stages. These approaches utilize large datasets from electronic medical records and neuroimaging studies to identify patterns indicative of diseases like AD and PD [7] [8] [33] [34] [35].

The application of AI technologies not only improves diagnostic processes but also has the potential to revolutionize preventive healthcare strategies, allowing for early intervention that could significantly alter disease trajectories and improve patient outcomes [4][6].

AI Technologies in Healthcare

Artificial Intelligence (AI) is rapidly transforming the landscape of healthcare by introducing innovative technologies that enhance patient care and diagnosis. These advancements are particularly significant in the realms of early detection and preventive healthcare, specifically for neurodegenerative disorders.

Key Technologies

Machine Learning and Deep Learning

Machine learning (ML) and deep learning (DL) are subsets of AI that play a crucial role in healthcare applications. ML algorithms are designed to recognize patterns in large datasets, allowing for effective diagnosis and treatment prediction. For instance, supervised learning trains algorithms using labeled datasets to identify underlying patterns, while unsupervised learning identifies patterns without prior labels [15] [16] [38] [39] [41]. Deep learning, on the other hand, employs multi-layered neural networks that can process and analyze complex data inputs, often leading to enhanced accuracy in detecting subtle changes in medical images that may indicate early signs of diseases [17] [2].

Natural Language Processing

Natural Language Processing (NLP) is another vital technology used in healthcare AI. NLP algorithms enable the interpretation and generation of human language, facilitating efficient patient-physician communication and automating administrative tasks. This technology supports clinical decision-making by extracting meaningful information from unstructured data, such as clinical notes and patient histories [9] [11].

Computer Vision

Computer vision is essential for medical imaging, where AI algorithms analyze images from various modalities such as MRI, CT scans, and retinal imaging. Advanced machine learning techniques can detect abnormalities that may not be visible to the naked eye, thereby improving early diagnosis of conditions such as Alzheimer's disease and other neurodegenerative disorders [17] [2]. This capability allows for non-invasive screening methods that enhance patient outcomes through timely interventions.

Applications in Preventive Healthcare

AI technologies have shown significant potential in preventive healthcare, particularly in the early diagnosis of neurodegenerative disorders. By leveraging large datasets, AI tools can identify risk factors and predict disease onset, enabling healthcare providers to implement preventive measures before the onset of symptoms. AI algorithms can assist in developing personalized treatment plans tailored to individual patient profiles, thereby optimizing care and improving quality of life [9] [10] [16].

Challenges and Opportunities

Despite the promising advancements, the integration of AI technologies in healthcare also faces several challenges. Issues such as data privacy, algorithmic bias, and the need for human oversight in clinical decision-making must be addressed to ensure the responsible deployment of AI systems in patient care [11] [10]. As research continues to advance, the opportunities for AI to enhance healthcare delivery and patient outcomes are vast, paving the way for a future where preventive healthcare is more effective and accessible [15] [17].

Deep Learning Framework for Early Diagnosis

Deep learning (DL) frameworks have emerged as powerful tools for the early diagnosis of neurodegenerative disorders, integrating advanced computational techniques with medical data to enhance predictive accuracy and clinical utility. Recognizing the pivotal role of early diagnosis in effective intervention, these frameworks focus on various data modalities, such as imaging, voice measures, and other biomarkers, to provide a comprehensive analysis of patient health [18] [19].

Conceptual Foundations

The framework begins with a thorough conceptual understanding of deep learning models, which encompasses data processing, model building, and interpretation. These models are designed to handle multi-modal data, capturing intricate inter-modal relationships that facilitate more effective and personalized treatment strategies [18] [20]. For instance, convolutional neural networks (CNNs) are adept at extracting spatial features from neuroimaging data, making them particularly suitable for analyzing high-dimensional datasets commonly found in neurodegenerative research [21] [12].

METHODOLOGICAL APPROACHES

Current research predominantly employs feature-level fusion for multimodal data integration, allowing for high-resolution data analysis and enhanced model generalization. However, this approach also raises challenges related to computational demands and data imbalance across modalities [21]. Consequently, there is growing interest in exploring decision-level fusion methods, which offer greater adaptability to diverse data types and reduced computational complexity. This balance between feature-level and decision-level strategies is crucial for optimizing the efficiency and scalability of DL models in clinical applications [21].

Addressing Challenges

Despite the potential benefits, several limitations persist in the application of AI in neurology. The "black box" nature of many DL algorithms raises concerns about interpretability, which can hinder trust and adoption among healthcare providers [12]. To address this issue, researchers are advocating for the incorporation of explainable AI (XAI) tools that enhance the interpretability of models while maintaining their predictive power. Bridging the gap between AI technologies and clinical applicability will require not only improved interpretability but also standardized practices in data collection and processing to ensure robust model performance across varied patient populations [21] [22].

Future Directions

The integration of artificial intelligence (AI) into preventive healthcare, particularly for the early diagnosis of neurodegenerative disorders, presents numerous opportunities and challenges that warrant further exploration. Despite significant advancements, the translatable potential of AI technologies to clinical practice remains under scrutiny, highlighting the need for more extensive studies to demonstrate their real-world value and effectiveness [15].

Advancements in AI Technologies

AI has evolved from early expert systems to sophisticated machine learning models capable of processing vast amounts of healthcare data. These innovations have the potential to enhance the accuracy and efficiency of diagnostic tools, particularly in the realm of neurodegenerative diseases such as Alzheimer's and Parkinson's [23]. By leveraging machine learning and deep learning techniques, researchers aim to improve diagnostic accuracy and facilitate earlier intervention, which is crucial in managing these conditions effectively [14] [23].

Addressing Integration Challenges

The transition from traditional reactive healthcare models to proactive preventive approaches necessitates overcoming several challenges. One significant hurdle is the integration of patient-generated data from wearable devices and mobile applications into clinical workflows. Healthcare providers must develop the infrastructure needed to harness this data effectively, ensuring interoperability with existing electronic health record (EHR) systems [24]. Government initiatives aimed at promoting standardized APIs for health data access are pivotal in addressing these integration challenges and facilitating seamless data sharing [24] [25].

Emphasizing Ethical Considerations

As AI technologies advance, ensuring their ethical deployment is paramount. Addressing concerns about privacy, bias, and equitable access to AI-driven healthcare solutions will be critical in gaining public trust and acceptance. Future research should focus on developing frameworks that prioritize ethical standards and promote the responsible use of AI in healthcare settings [10] [14].

Clinical Trials and Real-World Applications

Continued clinical trials and real-world studies will be essential to validate AI algorithms and ensure they deliver consistent results across diverse patient populations and clinical environments [14] [24]. As researchers refine AI models, collaboration between academia, industry, and healthcare providers will be necessary to translate these innovations into practical applications that improve patient outcomes and reduce healthcare costs.

Applications and Case Studies

Overview of AI Applications in Neurodegenerative Disorders

Artificial intelligence (AI) has shown great promise in the realm of preventive health-care, particularly for the early diagnosis and management of neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. By leveraging vast amounts of personal data, AI technologies facilitate early detection, personalized therapies, and continuous patient monitoring, thereby improving patient outcomes and healthcare efficiency [26] [27]. However, despite the growth in research, more studies are needed to translate these findings into clinical practice and establish their real-world value [15].

Use Cases in Early Detection and Diagnosis

AI applications in eHealth are rapidly evolving, showcasing various use cases that highlight their potential in early detection and diagnosis. For instance, AI algorithms are designed to analyze patterns in neuroimaging data, which can assist in identifying early markers of diseases like Alzheimer's [26]. Additionally, AI-driventools have been developed for continuous monitoring of patients, enabling healthcare professionals to detect changes in patient conditions more promptly than traditional methods allow [12] [11]. Figure 1 shows training and validation accuracy curves for different CNN architectures. The results reflect the capacity of both custom-built and transfer learning models to generalize over the dementia MRI dataset, with certain architectures (e.g., VGG16, ResNet50) demonstrating more rapid convergence and superior validation performance. [42]



Figure 1 Selected plots depicting accuracy values achieved by the CNN-based models during training and validation: (a) Accuracy values achieved by Custom CNN 128 model; (b) Accuracy values achieved by Custom CNN 1024 model; (c) Accuracy values achieved by ResNet50-based model; (d) Accuracy values achieved by VGG16-based model.

Personalized Treatment Approaches

Personalized treatment, often referred to as precision medicine, is another significant area where AI plays a crucial role. By analyzing extensive datasets, including patient histories and genetic information, AI can recommend tailored treatment plans that are more effective and safer for individual patients. This has been particularly beneficial for conditions like epilepsy and Parkinson's disease, where treatment responses can vary widely among patients [12] [11]. For example, AI can optimize Deep Brain.

Figure 2 illustrates representative axial brain slices from the ADNI dataset used in our study, segmented and labeled into Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI), and Cognitively Normal (CN) categories. This visual depiction reinforces the foundational role of structured labeling in enabling CNN-based classification. [42]



Figure 2 Sample of a few chosen brain ROIs with their associated labels.

Stimulation (DBS) settings based on patient data, enhancing the quality of life for those undergoing treatment [12]. Figure 3 presents Grad-CAM heatmaps overlaid on MRI slices. These highlight class-discriminative regions corresponding to known biomarkers, including the hippocampus and medial temporal lobe. Incorporating such interpretability methods ensures both clinical relevance and transparency of model decisions. [42]



Figure 1 Visualization of the Grad-CAM heatmaps overlaid on the sample outputs, highlighting specific brain areas responsible for the prediction: (a) Heatmaps generated by a shallow CNN-based model with a small number of convolutional layers and filters; (b) Heatmaps generated by a deep CNN-based model with a large number of convolutional layers and filters.

Challenges and Future Directions

Despite the promising applications of AI in neurodegenerative disorder management, several challenges remain. There is a pressing need for diverse and high-quality data to train AI models effectively, as biases in training data can lead to inequitable healthcare outcomes [15]. Moreover, integrating AI tools into existing clinical work-flows poses significant logistical challenges, requiring substantial investment in infrastructure and training for healthcare professionals [21] [14].

Future research must focus on prospective studies to assess the true utility of AI systems in clinical settings, as the majority of current studies rely on retrospective data, which may not accurately reflect real-world performance [28] [14]. Furthermore, the establishment of regulatory frameworks to ensure the safety and efficacy of AI-driven medical devices and applications will be critical for their widespread adoption in clinical practice [21] [14]. To contextualize the design of our proposed deep learning framework for early diagnosis of neurodegenerative disorders, we refer to the AI pipeline structure presented in *Figure 1* of a recent study published in *NPJ Digital Medicine* (2024) [43]. This figure outlines a generalized architecture for medical AI applications that integrates core components such as data acquisition, preprocessing, model training, classification, and output interpretation. While our study differs in terms of imaging modality (brain MRI vs. retinal scans) and specific network architectures, the referenced figure provides a well-aligned conceptual model. It captures the essential elements that are also embedded in our system, including slice-based image preprocessing, convolutional neural network (CNN) classification, and interpretability using Grad-CAM heatmaps.

By referencing this figure, we aim to visually anchor the reader's understanding of our approach within an established AI diagnostic framework, highlighting its suitability for preventive healthcare applications. Our adaptations of this model focus on 2D MRI slice processing and multi-class classification to differentiate between cognitively normal individuals, MCI, and Alzheimer's patients at early stages.



Figure 4 End-to-end pipeline of the proposed deep learning framework for early neurodegenerative disorder diagnosis. Inspired by Figure 1 from NPJ Digital Medicine *(2024), this pipeline integrates MRI acquisition, preprocessing, classification, and interpretability via Grad-CAM to support clinical decision-making.*

Challenges and Limitations

Patient Privacy Concerns

The implementation of AI in preventive healthcare raises significant patient privacy concerns. Key issues include the effectiveness of de-identification of data, the risk of data breaches, and ensuring that companies responsible for storing and analyzing patient information maintain robust security measures. There is also a pressing need for accountability regarding patients' privacy and data security. [29] [15] As healthcare organizations increasingly rely on AI-driven tools, the risk of unauthorized access to sensitive patient data intensifies, highlighting the need for stringent oversight and protection mechanisms. [30]

Ethical Considerations and Algorithmic Bias

Ethical dilemmas surrounding AI also extend to potential biases in algorithmic decision-making. If the data used to train AI systems lacks diversity or is not representative of the patient population, this can lead to biased outcomes, further exacerbating existing health disparities. This poses a significant challenge, as inaccurate diagnoses and suboptimal treatment options can disproportionately affect marginalized groups, raising serious ethical concerns in clinical applications of AI. [9] [10] [12] Furthermore, accountability in instances of AI errors remains ambiguous, complicating trust in AI solutions among healthcare providers and patients alike. [9]

Regulatory Challenges

Regulatory frameworks currently lag behind the rapid advancement of AI technologies in healthcare. The absence of a comprehensive global legal and regulatory framework for AI in healthcare means that issues of patient agency, consent, and data protection are inadequately addressed. Efforts such as the European Commission's proposed legislation aim to establish harmonized rules, yet many jurisdictions, including Canada, have yet to implement tailored regulations for AI applications in health-care. [13] [16] As a result, developers and healthcare providers face uncertainties regarding compliance and operational guidelines, which could hinder the adoption and effectiveness of AI technologies in clinical settings. [13]

Training and Workforce Adaptation

Effective implementation of AI tools necessitates significant training for the healthcare workforce. Medical professionals must be equipped not only to use these technologies but also to interpret the results effectively and integrate them into patient care strategies. This requires a substantial realignment of medical education and training programs, emphasizing the importance of AI literacy for future healthcare providers. [12] The current lack of standardized training may present obstacles to the widespread adoption of AI technologies in clinical practice, limiting their potential benefits in preventive healthcare.

Ethical Considerations

The integration of artificial intelligence (AI) into healthcare, particularly for preventive measures and early diagnosis of neurodegenerative disorders, raises significant ethical concerns that must be carefully addressed. Central to these concerns are issues related to patient data privacy, bias in AI algorithms, and the transparency of AI decision-making processes.

Patient Privacy and Data Security

One of the foremost ethical dilemmas in deploying AI in healthcare involves protecting patient privacy and ensuring data security. AI systems often rely on large datasets to train and validate algorithms, raising the risk of data breaches and unauthorized access to sensitive patient information. [15] [30] Even when data is anonymized, there remains a substantial risk that individuals can be re-identified, thus compromising their privacy. [31] [13] Furthermore, the transfer of healthcare data between institutions often lacks sufficient oversight, exacerbating vulnerabilities to data misuse. [30]

As the collection of data becomes ubiquitous, there is a growing call for a shift from merely controlling data collection to emphasizing "ethical data stewardship." This approach focuses on how data is handled post-collection, advocating for transparency and accountability in AI practices to ensure responsible management of patient information. [16]

Bias and Fairness

Another critical ethical concern is the potential for AI systems to perpetuate biases and exacerbate existing disparities in healthcare outcomes. Data used to train AI algorithms may inadvertently contain biases, leading to skewed recommendations that do not equitably serve all demographic groups. [27] [32] This raises ethical dilemmas as healthcare professionals must navigate decisions that could unfairly impact marginalized populations.

Ensuring fairness and accountability in AI applications necessitates ongoing research to identify and mitigate biases in healthcare technologies. [12]

Transparency and Accountability

The "black box" phenomenon poses significant challenges to trust in AI systems. The opaque nature of many AI algorithms makes it difficult for clinicians and patients to understand how decisions are made, which is particularly concerning in medical contexts where patient safety is paramount. [2] Without clarity regarding the decision-making processes of AI, validating AI recommendations can become problematic, leading to skepticism about their reliability. [12] To foster trust in AI-driven healthcare solutions, it is crucial to promote transparency in AI algorithms and hold developers and providers accountable for their systems' decisions. [32]

References

[1] Yousefi, M., Akhbari, M., Mohamadi, Z., Karami, S., Dasoomi, H., Atabi, A., Sarkeshikian, S. A., Abdoullahi Dehaki, M., Bayati, H., Mashayekhi, N., Varmazyar, S., Rahimian, Z., Asadi Anar, M., Shafiei, D., & Mohebbi, A. (2024). Machine learning based algorithms for virtual early detection and screening of neurodegenerative and neurocognitive disorders: A systematic- review. Frontiers in Neurology, 15, Article 1413071. https://doi.org/10.3389/fneur.2024.1413071

[2] Tukur, H. N., Uwishema, O., Akbay, H., Sheikhah, D., & Silva Correia, I. F. (2025, May 6). AI- assisted ophthalmic imaging for early detection of neurodegenerative diseases. International Journal of Emergency Medicine, 18, Article 90. https://doi.org/10.1186/s12245-025-00870-y

[3] Mirkin, S., & Albensi, B. C. (2023, April 18). Should artificial intelligence be used in conjunction with neuroimaging in the diagnosis of Alzheimer's disease? Frontiers in Aging Neuroscience, 15, Article 1094233. https://doi.org/10.3389/fnagi.2023.1094233

[4] Villamarin Rodriguez, R., Kannan, H., Revathi T., Shaikh, K., & Bekal, S. (2024). Deep learning approaches for early diagnosis of neurodegenerative diseases. IGI Global.

[5] Ayyappan, V., & Coffin, J. (2024, January 3). Artificial intelligence in diagnosing medical conditions and impact on healthcare. MGMA. Retrieved July 14, 2025, from https://www.mgma.com/articles/artificial-intelligence-in-diagnosing-medical-conditions-and-impact-on-healthcare

[6] Pal, S., Kaushik, A., Goel, F., Pal, A., & Garg, V. K. (2025). Revolutionizing early diagnosis: The role of artificial intelligence in neurodegenerative disorders. *Journal of Advanced Scientific Research*, *16*(1), [Article number if available]. https://sciensage.info

[7] Bavli, I., Ho, A., Mahal, R., & McKeown, M. (2024). Ethical concerns around privacy and data security in AI health monitoring for Parkinson's disease: Insights from patients, family members, and healthcare professionals. AI & Society. Advance online publication. https://doi.org/10.1007/s00146-023-01843-6

[8] Raza, M. L., Hassan, S. T., Jamil, S., Hyder, N., Batool, K., Walji, S., & Abbas, M. K. (2025, May 2). Advancements in deep learning for early diagnosis of Alzheimer's disease using multimodal neuroimaging: Challenges and future directions. Frontiers in Neuroinformatics, 19, Article 1557177. https://doi.org/10.3389/fninf.2025.1557177

[9] Undergraduate Research Apprentice Program. (n.d.). Advancing neurodegenerative disease diagnosis with artificial intelligence [Project description]. University of California, Berkeley. Retrieved July 14, 2025, from https://urapprojects.berkeley.edu/detail.php?id=20301-1

[10] Office of the Victorian Information Commissioner. (n.d.). Artificial intelligence and privacy – Issues and challenges. Retrieved July 14, 2025, from https://ovic.vic.gov.au/privacy/resources-for-organisations/artificial-intelligence-and-privacy-issues-and-challenges/

[11] Echelon Health. (n.d.). Artificial intelligence and early disease detection in preventative health assessments. Echelon Health. Retrieved July 14, 2025, from https://www.echelon.health/the-role-of-ai-in-early-disease-detection/
[12] Park University. (2024, December 2). AI in healthcare: Enhancing patient care and diagnosis. Park University Blog. Retrieved July 14, 2025, from https://www.park.edu/blog/ai-in-healthcare-enhancing-patient-care-and-diagnosis/
[13] Alowais, S. A., Alghamdi, S. S., Alsuhebany, N., Alqahtani, T., Alshaya, A. I., Almohareb, S. N., … Albekairy, A. M. (2023, September 22). Revolutionizing healthcare: The role of artificial intelligence in clinical practice. BMC Medical Education, 23, Article 689. https://doi.org/10.1186/s12909-023-04698-z
[14] Dankwa-Mullan, I. (2024, August 22). Health equity and ethical considerations in using artificial intelligence in public health and medicine [Commentary]. Preventing Chronic Disease, 21, Article E64. https://doi.org/10.5888/pcd21.240245 cdc.gov+6cdc.gov+6cdc.gov+6
[15] Rodriguez, R. V., Kannan, H., Revathi, T., Shaikh, K., & Bekal, S. (Eds.). (2024). Deep learning approaches for early diagnosis of neurodegenerative diseases. IGI Global. https://doi.org/10.4018/979-8-3693-1281-0
[16] Zhou, Y., Patel, D., & Zhang, J. (2022). Machine learning and deep learning models for early- stage detection of Alzheimer's disease and its proliferation in the human brain. In Artificial Intelligence in Medical Imaging (pp. 45–68). Elsevier. https://doi.org/10.1016/B978-0-323-90277-9.00024-9
[17] Termine, A., Fabrizio, C., Strafella, C., Caputo, V., Petrosini, L., Caltagirone, C., Giardina, E., & Cascella, R. (2021). Multi- layer picture of neurodegenerative diseases: Lessons from the use of big data through artificial intelligence. Journal of Personalized Medicine, 11(4), 280. https://doi.org/10.3390/jpm11040280
[18] Liu, H., Zhang, X., & Liu, Q. (2025, February 20). A review of AI- based radiogenomics in neurodegenerative disease. Frontiers in Big Data, 8. https://doi.org/10.3389/fdata.2025.1515341
[19] AbuAlrob, M. A., & Mesraoua, B. (2024, October 11). Harnessing artificial intelligence for the diagnosis and treatment of neurological emergencies: A comprehensive review of recent advances and future directions. Frontiers in Neurology. https://doi.org/10.3389/fneur.2024.1485799
[20] Chaki, J., & Woźniak, M. (2023). Deep learning for neurodegenerative disorder (2016 to 2022): A systematic review. Biomedical Signal Processing and Control, 80, Article 104223. https://doi.org/10.1016/j.bspc.2022.104223
[21] Gaur, L., Siarry, P., Abraham, A., & Castillo, O. (2024, January 19). Editorial: Advancements of deep learning in medical imaging for neurodegenerative diseases. Frontiers in Neuroscience, 18, Article 1361055. https://doi.org/10.3389/fnins.2024.1361055
[22] American Hospital Association. (2023, May 9). How AI is improving diagnostics, decision-making, and care. AHA Center for Health Innovation MarketScan. Retrieved July 14, 2025, from https://www.aha.org/aha-center-health-innovation-market-scan/2023-05-09-how-ai-improving-diagnostics-decision-making-and-care
[23] Amplyfi. (n.d.). AI- driven predictive and preventive healthcare. Amplyfi. Retrieved July 14, 2025, from https://amplyfi.com/blog/ai-driven-predictive-and-preventive-healthcare/
[24] Miller Media 7. (n.d.). The future of preventative healthcare: AI, wearables, and data analytics. Miller Media 7. Retrieved July 14, 2025, from https://millermedia7.com/the-future-of-preventative-healthcare-ai-wearables-and-data-analytics/

[25] Popescu, D., Iordache, A., & Rusu, G. (2024). Ethical considerations on the use of AI technology in eHealth applications for neurodegenerative diseases. Revista Română de Informatică şi Automatică, 34(1). https://rria.ici.ro/en/vol-34-no-1-2024/ethical-considerations-on-the-use-of-ai-technology-in-ehealth-applications-for-neurodegenerative-diseases/
[26] McCormack, J. (2024, February 23). Ethical issues loom as artificial intelligence shows promise for health information. Journal of AHIMA. https://journal.ahima.org/page/ethical-issues-loom-as-artificial-intelligence-shows-promise-for-health-information
[27] Kelly, C. J., Karthikesalingam, A., Suleyman, M., Corrado, G., & King, D. (2019). Key challenges for delivering clinical impact with artificial intelligence. BMC Medicine, 17, Article 195. https://doi.org/10.1186/s12916-019-1426-2
[28] Loeb & Loeb LLP. (2023, October). Navigating health data privacy in AI—Balancing ethics and innovation. Loeb & Loeb. https://www.loeb.com/en/insights/publications/2023/10/navigating-health-data-privacy-in-ai-balancing-ethics-and-innovation
[29] Alation. (2025, January 16). Ethics of AI in healthcare: Navigating privacy, bias, and trust in 2025. Alation. https://www.alation.com/blog/ethics-of-ai-in-healthcare-privacy-bias-trust-2025/
[30] Murdoch, B. (2021). Privacy and artificial intelligence: Challenges for protecting health information in a new era. BMC Medical Ethics, 22(1), 122. https://doi.org/10.1186/s12910-021-00687-3
[31] Tilala, M. H., Chenchala, P. K., Choppadandi, A., Kaur, J., Naguri, S., Saoji, R., & Devaguptapu, B. (2024). Ethical considerations in the use of artificial intelligence and machine learning in health care: A comprehensive review. Cureus, 16(6), eXXXX. https://doi.org/10.7759/cureus.XXXX (PMCID: PMC11249277)
[32] HITRUST Alliance. (2023, November 15). The ethics of AI in healthcare: Building a future of trust and responsibility. HITRUST Alliance. https://hitrustalliance.net/blog/the-ethics-of-ai-in-healthcare
[33] Shahid, M. A., Iftikhar, M. A., Gondal, Z. A., Adnan, M., & Rathore, S. (2018, December). Object size measurement through images: An application to measuring human foot size. In 2018 International Conference on Frontiers of Information Technology (FIT) (pp. 298-302). IEEE.
[34] Shahid, M. A., Safyan, M., & Mustafa, A. (2025). MALWARE ANALYSIS AND DETECTION FOR MICROSOFT TECHNOLOGIES. Kashf Journal of Multidisciplinary Research, 2(01), 57-69.
[35] Shahid, M. A., Safyan, M., & Pervez, Z. (2024). Improvising the Malware Detection Accuracy in Portable Document Format (PDFs) through Machine Learning Classifiers. Review of Applied Management and Social Sciences, 7(4), 201-221.
[36] Khan, A. A., Aqsa, T., & Shahid, M. A. (2024). Flood pattern variation in Pakistan: a comprehensive study on water quantity and rainfall data from 1992 to 2022. Pakistan Research Journal of Social Sciences, 3(2).
[37] Khan, A. A., Aqsa, T., & Shahid, M. A. (2023). Urban Vegetation and Population Variability in Pakistan. A GIS and Remote Sensing Analysis of Peshawar, Karachi, and Lahore (1990-2020). Pakistan Research Journal of Social Sciences, 2(4).
[38] Shahid, M. A., & Mustafa, A. (2025). Microagents as a Sustainable Solution to Reduce Global Warming. Journal of Social Signs Review, 3(05), 89-94.
[39] Shahid, M. A., & Mustafa, A. (2025). Use of Artificial Intelligence (AI) in Global Warming. Journal of Social Signs Review, 3(4), 304-312.
[40] Khan, A. A., Aqsa, T., & Shahid, M. A. (2023). Seismic Shockwaves: Analyzing the Impact of the Earthquake Hazards in Pakistan from 1922-2023 through GIS Modeling and

Socioeconomic Consequences. Pakistan Research Journal of Social Sciences, 2(3).

[41] Shahid, M. A., Safyan, M., & Mustafa, A. Machine Learning based Emotion Recognition using Facial Action Units over Edge-based Academic Infrastructure.

[42] Knapinska, Z., & Mulawka, J. (2025). *Patient-Tailored Dementia Diagnosis with CNN-Based Brain MRI Classification*. *Applied Sciences, 15*(9), 4652. https://doi.org/10.3390/app15094652

[43] Li, Z., Wang, M., Zhang, H., et al. (2024). Deep learning for dementia prediction from retinal images: an interpretable AI system. *NPJ Digital Medicine*, 7(1), Article 67. https://www.nature.com/articles/s41746-024-01292-5